|
Market Cap (4-Jul) $3,153,122 (199th) |
Close (30-Jun) $0.091 |
Volume (30-Jun) 50,159,971 |
Shortsold (19-Jun) 392,315,164 (5.25%) (41st) |
|
52w High $2.75 |
52w Low $0.340 |
P/E - |
EPS -0.6 |
IMU released this announcement to the ASX on 27 September 2022, 9:01. The announcement is not marked as price sensitive, and is 5 page(s) in length and 223.26kb in size.
This announcement originated from ALA.
You can view all announcements from IMU and see how they appear on a price chart on the announcements page.
At the date of this announcement, IMU was 4.639% short sold according to ASIC data. It was ranked the 47th most shorted stock on the ASX. It is now ranked as the 41st most shorted stock on the ASX with 5.254% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from IMU | |
|---|---|
| Change of Director's Interest Notice | 30 June 2023, 16:33 |
| HER-Vaxx induced antibodies correlated with tumour reduction | 30 June 2023, 8:40 |
| Imugene PD1-Vaxx patent extended to 2040 | 29 June 2023, 8:39 |
| ALA iNKT therapy and IMU onCARlytics - correction | 27 September 2022, 9:01 |
| ALA: Investor Presentation Imugene Arovella Therapies | 26 September 2022, 10:33 |
| Preclinical trial of ALA iNKT therapy and IMU onCARlytics | 26 September 2022, 9:55 |
| First patient IV dosed in VAXINIA Phase 1 clinical trial | 21 September 2022, 9:29 |
You must be logged in to post a reply.
Imugene 